Janus激酶抑制剂诱导的炎症性肠病相关痤疮:一项国际多中心回顾性队列研究
该国际多中心回顾性队列研究连续纳入接受JAK抑制剂后出现痤疮的炎症性肠病患者,评估痤疮的临床特征、患病率、对生活质量的影响及抗痤疮治疗有效性。在2183例接受JAK抑制剂治疗的炎症性肠病患者中,272例出现痤疮,乌帕替尼、托法替布和非戈替尼的粗患病率分别为15.9%、4.3%和1.9%,乌帕替尼和托法替布呈剂量依赖性关系。
要点
- 在2183例接受JAK抑制剂治疗的炎症性肠病患者中,272例出现痤疮。
- 乌帕替尼、托法替布和非戈替尼的痤疮粗患病率分别为15.9%、4.3%和1.9%。
- 有寻常痤疮病史与发生严重JAK抑制剂相关痤疮的比值比显著增加相关(比值比4.88,95%CI 2.88-31.7,P=0.0003)。
核心结论
- 这是首个描述接受JAK抑制剂治疗的炎症性肠病患者中该不良事件特征的研究,并呈现了所有免疫介导疾病中最大规模的JAK抑制剂诱导痤疮病例队列。
- 痤疮是导致显著心理负担的常见不良反应,早期识别、主动咨询和及时干预(如减量或转诊皮肤科)对管理该副作用至关重要。
研究设计与样本
- 国际多中心回顾性队列研究,连续纳入接受JAK抑制剂治疗后出现痤疮的炎症性肠病患者。
- 主要目标为评估痤疮的临床特征,次要目标包括确定痤疮患病率、对生活质量的影响及抗痤疮治疗的有效性。
主要发现
- 在2183例接受JAK抑制剂治疗的炎症性肠病患者中,272例出现痤疮。
- 痤疮粗患病率:乌帕替尼15.9%,托法替布4.3%,非戈替尼1.9%,乌帕替尼和托法替布观察到剂量依赖性关系。
- 痤疮主要影响30-50岁患者,多数病例为轻中度严重程度。
- 有寻常痤疮病史与发生严重JAK抑制剂相关痤疮的比值比显著增加相关(比值比4.88,95%CI 2.88-31.7,P=0.0003),并与痤疮相关皮肤并发症的比值比显著增加相关(比值比3.92,95%CI 1.56-10.11,P=0.004)。
- 三分之一患者报告负面心理社会影响,40%接受了药物治疗,18%出现痤疮的患者需要JAK抑制剂减量或停药,尽管多数患者无严重疾病。
临床怎么用
- 作者认为,早期识别、主动咨询和及时干预(如减量或转诊皮肤科)对管理该副作用至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: JAK inhibitor-associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in patients with inflammatory bowel disease (IBD). METHODS: This international, multicenter, retrospective cohort study consecutively enrolled JAK-inhibitor-treated patients with IBD who subsequently developed acne. The primary objective was to evaluate the clinical characteristics of acne. Secondary objectives included determining acne prevalence, impact on quality of life, and antiacne treatment effectiveness. RESULTS: Among 2183 JAK inhibitor-treated patients with IBD, 272 developed acne. The crude prevalence rates of acne were 15.9% for upadacitinib, 4.3% for tofacitinib, and 1.9% for filgotinib, with dose-dependent relationships observed for upadacitinib and tofacitinib. Acne predominantly affected patients aged 30-50 years; most cases were mild-moderate in severity. A prior history of acne vulgaris was associated with significantly increased odds of developing severe JAK inhibitor-associated acne (odds ratio, 4.88; 95% confidence interval, 2.88-31.7; P = .0003) and acne-related skin complications (odds ratio, 3.92; 95% confidence interval, 1.56-10.11; P = .004). One-third of patients reported a negative psychosocial impact, and 40% received pharmacologic intervention. Eighteen percent of patients who developed acne required JAK inhibitor dose reduction or discontinuation, although most did not have severe disease. CONCLUSIONS: This is the first study characterizing this adverse event in JAK inhibitor-treated patients with IBD and presents the largest cohort of JAK inhibitor-induced acne cases across all immune-mediated diseases. Acne is a common adverse effect resulting in significant psychological burden. Early identification, proactive counseling, and timely interventions, such as dose reduction or referral to dermatology, are crucial in managing this side effect.
引用
- Honap S, Temido MJ, Shakweh E, et al. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 40505791. doi:10.1016/j.cgh.2025.04.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。